Examining Different Sequence Effects of CDK4/6 Inhibitor Combinations on Actual Real-World Outcomes of Treatment in Patients with Hormone Receptor–Positive and HER2-Negative Metastatic Breast Cancer

2020 Year in Review - Breast Cancer —January 25, 2021

Categories:

Breast Cancer

While progression-free survival was similar, overall survival was better in CDK4/6 inhibitor combinations as first-line therapy followed by everolimus combinations and chemotherapy.

In a poster presentation, Silvia Comis, MD, Senior Medical Director, Oncology-Therapeutic Science and Strategy, IQVIA, Milan, Italy, discussed clinical trials in which CDK4/6 inhibitors have shown clear benefits in terms of progression-free survival and overall survival. Despite this growing body of evidence suggesting their benefit in the clinical setting, best practices remain unresolved and persistent issues exist, such as optimal sequencing with other therapies when treating patients with hormone receptor–positive, HER2-negative metastatic breast cancer. Therefore, it is critically important to examine the range of CDK4/6 inhibitor combinations used in patients with hormone receptor–positive, HER2-negative metastatic breast cancer, in light of real-world evidence.

Researchers used IQVIA’s oncology US electronic health records for the fourth quarter of 2015 to the first quarter of 2020 to identify 16,017 patients with metastatic breast cancer aged ≥18 years with hormone receptor–positive, HER2-negative disease. Based on different sequential use of drugs, patients were organized into 4 cohorts. In the first cohort, hormonal therapy was used as first-line therapy followed by everolimus combinations, CDK4/6 inhibitor combinations, and chemotherapy. In the second cohort, CDK4/6 inhibitor combinations were used as first-line therapy, followed by everolimus combinations and chemotherapy. In the third cohort, everolimus combinations were used as first-line therapy followed by CDK4/6 inhibitor combinations and chemotherapy. In the fourth cohort, chemotherapy was used as first-line therapy as well as subsequent therapy.

Patient outcomes were analyzed for each cohort: progression (defined as time to next treatment), progression-free survival (defined as time to next treatment or death), and overall survival.

Statistically significant results between the first and second cohorts, generated by a test of proportions which demonstrated that more patients tend to live longer after they have been treated with CDK4/6 inhibitor combinations as first-line therapy, as shown by the second cohort at 80% compared with the first cohort at 87%. Due to the small total number of patients in the third cohort, statistical significance was not revealed.

On comparison between cohorts, more patients died in the fourth cohort in which chemotherapy was used as first-line therapy and subsequent therapy. Across cohorts, the median progression-free survival observed for CDK4/6 inhibitor combinations was 13.5 months.

The investigators concluded that based on this retrospective analysis, overall survival was better in the second cohort (CDK4/6 inhibitor combinations used as first-line therapy, followed by everolimus combinations and chemotherapy) when compared with other cohorts. However, progression-free survival during CDK4/6 inhibitor combinations was comparable. Future studies may focus on cohort demographics along with propensity score matching based on other variables and detailed CDK4/6 inhibitor combination analysis that may clarify these results.

Source: Comis S, Kandasamy T, Wu C, et al. Real-world evidence of CDK4/6 inhibitor combination effects on assessing outcome with different sequence of treatment among adult patients with HR+ and HER2- metastatic breast cancer. Ann Oncol. 2020;31(4_suppl). Abstract 307P.

Related Articles
Key Breast Cancer Abstracts in 2023 and Innovations in Ovarian Function Suppression:
Matteo Lambertini, MD, PhD, Erica Stringer-Reasor, MD, Director, Sara M. Tolaney, MD, MPH
|
Video Library
Please join Sara Tolaney, MD, MPH, Dana-Farber Cancer Center, Boston, MA; Erica Stringer-Reasor, MD, University of Alabama, Birmingham; and Matteo Lambertini, MD, PhD, University of Genoa, Italy, as they provide expert commentary on key breast cancer abstracts presented at the 2023 ASCO Annual Meetings that will impact young women with ER+/HER2- breast cancer.
Navigating Oral Therapy in Breast Cancer: Practice Strategies to Promote Medication Adherence
Video Library
The Academy of Oncology Nurse & Patient Navigators (AONN+) and Eli Lilly and Company Medical Affairs are pleased to present a live webinar designed to facilitate conversations with patients regarding adherence to breast cancer treatments. Attendees will have an opportunity to participate in a live Q&A following the presentation.
Improving Adherence to Oral Oncolytics in Breast Cancer: The Pivotal Role of Nurse Navigators
September 2022 Vol 13, No 9
Oral oncolytic drugs have a multitude of benefits for patients, including ease of use, improved quality of life, fewer clinic visits, and no need for IV therapy.
Last modified: August 10, 2023

Subscribe Today!

To sign up for our print publication or e-newsletter, please enter your contact information below.

I'd like to receive:

  • First Name *
    Last Name *
     
     
    Profession or Role
    Primary Specialty or Disease State
    Country